The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 01, 2020

Filed:

Apr. 08, 2015
Applicant:

Emory University, Atlanta, GA (US);

Inventors:

Keqiang Ye, Lilburn, GA (US);

Haian Fu, Decatur, GA (US);

Yuhong Du, Atlanta, GA (US);

Assignee:

Emory University, Atlanta, GA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 473/06 (2006.01); A61K 45/06 (2006.01); A61K 31/4015 (2006.01); A61K 31/4168 (2006.01); A61K 31/433 (2006.01); A61K 31/47 (2006.01); A61K 31/496 (2006.01); A61K 31/519 (2006.01); A61K 31/522 (2006.01); A61K 31/5355 (2006.01); C07D 207/452 (2006.01); C07D 215/06 (2006.01); C07D 257/04 (2006.01); C07D 273/02 (2006.01); C07D 277/54 (2006.01); C07D 285/135 (2006.01); C07D 471/04 (2006.01);
U.S. Cl.
CPC ...
C07D 473/06 (2013.01); A61K 31/4015 (2013.01); A61K 31/4168 (2013.01); A61K 31/433 (2013.01); A61K 31/47 (2013.01); A61K 31/496 (2013.01); A61K 31/519 (2013.01); A61K 31/522 (2013.01); A61K 31/5355 (2013.01); A61K 45/06 (2013.01); C07D 207/452 (2013.01); C07D 215/06 (2013.01); C07D 257/04 (2013.01); C07D 273/02 (2013.01); C07D 277/54 (2013.01); C07D 285/135 (2013.01); C07D 471/04 (2013.01);
Abstract

This disclosure relates to asparagine endopeptidase inhibitors for managing cancer and compositions related thereto. In certain embodiments, the asparagine endopeptidase inhibitors are substituted 3,7-dihydropurine-2,6-dione derivatives useful for treating or preventing metastasis, tumor growth, and/or cancer. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising an asparagine endopeptidase inhibitor and a pharmaceutically acceptable excipient. In certain embodiments, the disclosure relates to methods of treating a cancer comprising administering an effective amount of pharmaceutical composition a asparagine endopeptidase inhibitor disclosed herein to a subject in need thereof.


Find Patent Forward Citations

Loading…